alum adjuvant

DRUG4 trials

Sponsors

University of Alabama at Birmingham, Onyvax, University of Southern California, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Colorectal CancerHuman Immunodeficiency Virus (HIV)Human Immunodeficiency Virus PreventionIntraocular MelanomaMelanoma (Skin)

Phase 1

Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer

OnyvaxColorectal Cancer

Start: 2000-04-30Updated: 2013-09-20

Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma

CompletedNCT00004184

University of Alabama at BirminghamMelanoma (Skin)

Start: 1998-08-31End: 2001-06-30Target: 50Updated: 2013-04-12

Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults

CompletedNCT03783130

National Institute of Allergy and Infectious Diseases (NIAID)Human Immunodeficiency Virus (HIV), Human Immunodeficiency Virus Prevention

Start: 2019-03-07End: 2020-06-24Updated: 2021-08-12

Phase 2

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

CompletedNCT00031733

University of Southern CaliforniaIntraocular Melanoma, Melanoma (Skin)

Start: 2002-02-28End: 2007-11-30Updated: 2014-05-22

Related Papers

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial.

2022-06-0134 citations